CORAL GABLES, FL / ACCESSWIRE / March 14, 2019 / Over the last few months, the healthcare stock market has captivated media attention as companies in the healthcare sector have focused their efforts on developing innovative treatment options and care solutions for patients suffering from an assemblage of ailments. Given that the success of the healthcare industry is dependent on companies meeting the demands of patients who simply want to live healthy lives, any company taking a patient-centric focus to their healthcare framework has seen impressive gains in the first few months of 2019. Investors looking for potential opportunities could benefit from keeping tabs on the healthcare industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Hancock Jaffe Laboratories Inc (HJLI), Kitov Pharmaceuticals Ltd (KTOV), and Auris Medical Holding AG (EARS) are 4 healthcare companies heating up on Thursday.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care. At a time where consumers depend on healthcare companies to provide quality care solutions, Premier Health is prepared to meet the needs of its patients.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) found itself in headlines yesterday when the Company announced it is working with Bio Conscious Technologies to bring their artificial intelligence technology to Premier Health's active patient network. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, ''since the beginning, remote patient monitoring has been an integral component of our telemedicine app. DiaBits will enable our diabetic patients to dramatically increase glucose control and improve their quality of life. We are eager to work with the team at BCT to bring this innovative solution to our comprehensive telemedicine app.''
Hancock Jaffe Laboratories Inc (HJLI) saw impressive gains in the market on Thursday, with its shares soaring 46.55%, trading at $2.55 per share early in the afternoon. The Company yesterday announced that it has closed a private placement of 2,360,051 shares of its common stock for aggregate gross proceeds of approximately $2.7 million with various accredited investors, including participation by a member of HJLI's management. Investors did not receive warrants.
Robert Berman, CEO of Hancock Jaffe, said, ''in advance of key milestones including preliminary data for our VenoValve® first-in-human study, and our CoreoGraft® feasibility study, we wanted to strengthen our balance sheet and extend our operational runway. We remain confident with our projected timeline for these two major milestones at the end of the second quarter of 2019, and this financing will ensure that we are adequately capitalized through the release of our results."
Kitov Pharmaceuticals Ltd (KTOV), an innovative pharmaceutical company, reported its unaudited financial results for the year ended December 31, 2018, and provided investors with a business update in early February. Per the details of their updates, the Company's product, Consensi™, was approved by the U.S. FDA in June 2018 and is licensed for commercialization in the U.S., China, and South Korea.
Isaac Israel, CEO of Kitov Pharma, said, ''we are working productively with Coeptis Pharmaceuticals and its outstanding team to launch Consensi™ in the U.S. market to create better patient compliance and improved treatment for people living with osteoarthritis pain and hypertension. Additionally, we are very satisfied with the on-target execution of our NT-219 oncology program and we look forward to initiating clinical trials later this year.''
Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurology, today announced financial results for the fourth quarter and full year ended December 31, 2018.
Over the course of the year, the Company progressed with preparations for TRAVERS Phase 2 trial with AM-125 in acute vertigo. The TRAVERS trial will enroll 138 patients that suffer from acute vertigo following surgical removal of a vestibular schwannoma, a tumor growing behind the inner ear. The selection of clinical trial sites in several European countries and Canada has essentially been completed and the first approval from a competent authority has already been received.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid ''500,000'' shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: